Radioiodine Remnant Ablation: A Critical Review

Area of Science:

• Nuclear medicine
• Endocrinology
• Oncology

Background:

• Radioiodine remnant ablation (RRA) is a standard adjuvant therapy post-thyroidectomy for eliminating residual thyroid tissue and microscopic disease.
• Serum thyroglobulin (Tg) measurement is a crucial tumor marker for detecting recurrence, especially when thyroid tissue is absent.
• Concerns exist regarding remnant tissue hindering metastasis detection and potential anaplastic transformation.

Purpose of the Study:

• To evaluate the efficacy of different radioactive iodine doses for remnant ablation in thyroid cancer.
• To critically assess the necessity of conventional high-dose RRA.
• To establish the scientific basis for a new era of low-dose RRA.

Main Methods:

• Review of existing literature and clinical trials on radioactive iodine dosing for remnant ablation.
• Analysis of a prospective randomized clinical trial from India (1996) and recent studies from France and the UK.
• Comparison of dose-response curves for radioactive iodine in remnant ablation.

Main Results:

• A 1996 Indian study indicated that doses exceeding 50 mCi of radioactive iodine (131I) for remnant ablation showed a plateau in the dose-response curve.
• Recent studies from France and the UK corroborate these findings, demonstrating similar conclusions across different geographical regions.
• These consistent results support the efficacy of lower radioactive iodine doses for remnant ablation.

Conclusions:

• Conventional high-dose remnant ablation requires critical re-evaluation.
• Evidence from multiple international studies supports the effectiveness of low-dose radioactive iodine remnant ablation.
• A new era of low-dose remnant ablation is scientifically validated and gaining global acceptance.